Quaternary ammonium β-cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier

Biomacromolecules

Volumn 10, Issue 3, 2009, Pages 505-516

  Gil, Eun Seok ^a,b   Li, Jianshu ^c   Xiao, Huining ^c   Lowe, Tao Lu ^b,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF NEW BRUNSWICK   (Canada)

^d Tufts University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-CANCER DRUGS; ATR FT-IR; BLOOD-BRAIN BARRIERS; BOVINE BRAINS; CD COMPLEXES; CONCENTRATION OF; DOXORUBICIN; DRUG DELIVERY CARRIERS; ELECTRICAL RESISTANCES; HYDRODYNAMIC RADIUS; IN-VITRO; OCCLUDIN; P GLYCOPROTEINS; QUATERNARY AMMONIUM GROUPS; QUATERNARY AMMONIUMS; THERAPEUTIC AGENTS; TIGHT JUNCTIONS;

AMINES; AMMONIUM COMPOUNDS; BLOOD; CAPILLARITY; CONFOCAL MICROSCOPY; DATA STORAGE EQUIPMENT; DRUG DELIVERY; DYES; ENDOTHELIAL CELLS; FLOW CYTOMETRY; FLUID DYNAMICS; FOURIER TRANSFORM INFRARED SPECTROSCOPY; GLUCOSE; GLYCOPROTEINS;

NANOPARTICLES;

BETA CYCLODEXTRIN DERIVATIVE; CHOLESTEROL; DEXTRAN; DOXORUBICIN; GLYCOPROTEIN P; LUCIFER YELLOW; NANOCARRIER; NANOPARTICLE; OCCLUDIN; PROTEIN ZO1; QUATERNARY AMMONIUM DERIVATIVE; DRUG CARRIER;

ANIMAL CELL CULTURE; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONFOCAL MICROSCOPY; CONTROL GROUP; CONTROLLED STUDY; COW; DRUG CYTOTOXICITY; DRUG PENETRATION; ENDOCYTOSIS; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYDRODYNAMICS; IN VITRO STUDY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; ANIMAL; BOVINAE; BRAIN; CELL MEMBRANE PERMEABILITY; CHEMISTRY; CYTOLOGY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; SURFACE PROPERTY; VASCULARIZATION;

ANIMALS; BETA-CYCLODEXTRINS; BLOOD-BRAIN BARRIER; BRAIN; CATTLE; CELL MEMBRANE PERMEABILITY; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; NANOPARTICLES; PARTICLE SIZE; QUATERNARY AMMONIUM COMPOUNDS; SURFACE PROPERTIES;

BOVINAE;

EID: 65249177710     PISSN: 15257797     EISSN: None     Source Type: Journal    
DOI: 10.1021/bm801026k     Document Type: Article

References (58)

1. Pardridge, W. M. Adv. Drue Delivery Rev. 1999, 36, 299-321.
2. Jefferies, W. A.; Brandon, M. R.; Hunt, S. V.; Williams, A. F.; Gatter, K. C; Mason, D. Y. Nature 1984, 312, 162-163.
3. Huber, J. D.; Egleton, R. D.; Davis, T. P. Trends Neurosci. 2001, 24, 719-725.
4. Pan, W.; Banks, W. A.; Kastin, A. J. Brain Res. 1998, 788, 87-94.
5. Plotkin, S. R.; Banks, W. A.; Kastin, A. J. J. Neuroimmunol. 1996, 67, 41-47.
6. Tomas-Camardiel, M.; Venero, J. L.; Herrera, A. J.; De Pablos, R. M.; Pintor-Toro, J. A.; Machado, A.; Cano, J. J.Neurosci.Res. 2005, 80, 235-246.
7. Gumerlock, M. K.; Belshe, B. D.; Madsen, R.; Watts, C. J. Neurooncol. 1992, 12, 33-46.
8. Rapoport, S. I. Expert. Ovin. Invest. Drugs 2001, 10, 1809-1818.
9. Born, J.; Lange, T.; Kern, W.; McGregor, G. P.; Bickel, U.; Fehm, H. L. Nat. Neurosci. 2002, 5, 514-516.
10. Chamberlain, M. C. J. Neurooncol. 1998, 38, 135-140.
11. Kusuhara, H.; Sugiyama, Y. Drug Discoyery Today 2001, 6, 150-156.
12. Kemper, E. M.; Boogerd, W.; Thuis, I.; Beijnen, J. H.; van Tellingen, O. Cancer Treat. Rev. 2004, 30, 415-423.
13. Smith, M. W.; Gumbleton, M. J. Drue Targeting 2006, 14, 191-214.
14. Pardridge, W. M. Nat. Rev. Drug Discovery 2002, 1, 131-139.
15. Qian, Z. M.; Li, H.; Sun, H.; Ho, K. Pharmacol. Rev. 2002, 54, 561-587.
16. Thole, M.; Nobmanna, S.; Huwyler, J.; Bartmann, A.; Fricker, G. J. Drue Targeting 2002, 10, 337-344.
17. Huwyler, J.; Yang, J.; Pardridge, W. M. J. Pharmacol. Exp. Ther. 1997, 282, 1541-1546.
18. Shi, N. Y.; Pardridge, W. M. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 7567-7572.
19. Gao, Z. G.; Lee, D. H.; Kim, D. I.; Bae, Y. H. J. Drug Targeting 2005, 13, 391-397.
20. Lockman, P. R.; Mumper, R. J.; Khan, M. A.; Allen, D. D. Drug Dev. Ind. Pharm. 2002, 28, 1-13.
21. Soppimath, K. S.; Aminabhavi, T. M.; Kulkarni, A. R.; Rudzinski, W. E. J. Controlled Release 2001, 70, 1-20.
22. Kreuter, J. Adv. Drug Delivery Rev. 2001, 47, 65-81.
23. Vinogradov, S. V.; Batrakova, E. V.; Kabanov, A. V. Bioconiugate Chem. 2004, 15, 50-60.
24. Lockman, P. R.; Koziara, J. M.; Mumper, R. J.; Allen, D. D. J. Drue Targeting 2004, 12, 635-641.
25. Gulyaev, A. E.; Gelperina, S. E.; Skidan, I. N.; Antropov, A. S.; Kivman, G. Y.; Kreuter, J. Pharm. Res. 1999, 16, 1564-1569.
26. Kreuter, J. J. Nanosci. Nanotechnol. 2004, 4, 484-488.
27. Moghimi, S. M.; Hunter, A. C; Murray, J. C. Pharmacol. Rev. 2001, 53, 283-318.
28. Brownlie, A.; Uchegbu, I. F.; Schatzlein, A. G. Int. J. Pharm. 2004, 274, 41-52.
29. Szejtli, J. Chem. Rev. 1998, 98, 1743-1753.
30. Hirayama, F.; Uekama, K. Adv. Drug Delivery Rev. 1999, 36, 125-141.
31. Irie, T.; Uekama, K. J. Pharm. Sci. 1997, 86, 147-162.
32. Ohtani, Y.; Irie, T.; Uekama, K.; Fukunaga, K.; Pitha, J Biochem. Eur. J. 1989, 186, 17-22.
33. Perrin, J. H.; Field, F. P.; Hansen, D. A.; Mufson, R. A.; Torosian, G. Res. Commun. Chem. Pathol. Pharmacol. 1978, 19, 373-6.
34. Brewster, M. E.; Loftsson, T. Adv. Drug Delivery Rev. 2007, 59, 645-66.
35. Davis, M. E.; Brewster, M. E. Nat. Rev. Drug Discovery 2004, 3, 1023-1035.
36. Szente, L.; Szejtli, J. Adv. Drug Delivery Rev. 1999, 36, 17-28.
37. Leroylechat, F.; Wouessidjewe, D.; Andreux, J. P.; Puisieux, F.; Duchene, D. Int. J. Pharm. 1994, 101, 97-103.
38. Frijlink, H. W.; Visser, J.; Hefting, N. R.; Oosting, R.; Meijer, D. K. F.; Lerk, C. F. Pharm. Res. 1990, 7, 1248.
39. Rajewski, R. A.; Traiger, G.; Bresnahan, J.; Jaberaboansari, P.; Stella, V. J.; Thompson, D. O. J. Pharm. Sci. 1995, 84, 927-932.
40. Li, J. S.; Xiao, H. N.; Li, J. H.; Zhong, Y. P. Int. J. Pharm. 2004, 278, 329-342.
41. Tilloy, S.; Monnaert, V.; Fenart, L.; Bricout, H.; Cecchelli, R.; Monflier, E. Bioorg. Med. Chem. Lett. 2006, 16, 2154-2157.
42. Binkowski-Machut, C.; Hapiot, F.; Martin, P.; Cecchelli, R.; Monflier, E. Bioorg. Med. Chem. Lett. 2006, 16, 1784-1787.
43. Zhong, N.; Ohvo-Rekila, H.; Ramstedt, B.; Slotte, J. P.; Bittman, R. Langmuir 2001. 17, 5319-5323.
44. Chang, Y. S.; Munn, L. L.; Hillsley, M. V.; Dull, R. O.; Yuan, J.; Lakshminarayanan, S.; Gardner, T. W.; Jain, R. K.; Tarbell, J. M. Microvasc. Res. 2000, 59, 265-277.
45. Husain, N.; Ndou, T. T.; Delapena, A. M.; Warner, I. M. Appl. Svectrosc. 1992, 46, 652-658.
46. Zheng, Y.; Zuo, Z.; Chow, A. H. L. Int. J. Pharm. 2006, 309, 123-128.
47. Stover, T. C; Kim, Y. S.; Lowe, T. L.; Kester, M. Biomaterials 2008, 29, 359-369.
48. Monnaert, V.; Betbeder, D.; Fenart, L.; Bricout, H.; Lenfant, A. M.; Landry, C.; Cecchelli, R.; Monflier, E.; Tilloy, S. J. Pharmacol. Exp. Ther. 2004, 311, 1115-1120.
49. Machut-Binkowski, C; Hapiot, F.; Cecchelli, R.; Martin, P.; Monflier, E. J. Inclusion Phenom. Macrocyclic Chem. 2007, 57, 567-572.
50. Monnaert, V.; Tilloy, S.; Bricout, H.; Fenart, L.; Cecchelli, R.; Monflier, E. J. Pharmacol. Exp. Ther. 2004, 310, 745-751.
51. Arima, H.; Yunomae, K.; Morikawa, T.; Hirayama, F.; Uekama, K. Pharm. Res. 2004, 21, 625-634.
52. Jodoin, J.; Demeule, M.; Fenart, L.; Cecchelli, R.; Farmer, S.; Linton, K. J.; Higgins, C. F.; Beliveau, R. J. Neurochem. 2003, 87, 1010-1023.
53. Lu, W.; Wan, J.; She, Z.; Jiang, X. J. Controlled Release 2007, 118, 38-53.
54. Fenart, L.; Casanova, A.; Dehouck, B.; Duhem, C.; Slupek, S.; Cecchelli, R.; Betbeder, D. J. Pharmacol. Exp. Ther. 1999, 291, 1017-1022.
55. Karakotchian, M.; Fraser, I. S. Micron 2007, 38, 632-636.
56. Burns, E. M.; Dobben, G. D.; Kruckeberg, T. W.; Gaetano, P. K. Adv. Neurol. 1981, 30, 159-165.
57. Lu, W.; Tan, Y. Z.; Hu, K. L.; Jiang, X. G. Int. J. Pharm. 2005, 295, 247-260.
58. Tsuji, A. Ther. Drug Monit. 1998, 20, 588-590. BM801026K